Price
CHART BY
Frequently asked questions
What is Vanda Pharms's market capitalization?
The market capitalization of Vanda Pharms is $467.54M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Vanda Pharms?
Vanda Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.736. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Vanda Pharms's stock?
Currently, 5 analysts cover Vanda Pharms's stock, with a consensus target price of $15.50. Analyst ratings provide insights into the stock's expected performance.
What is Vanda Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Vanda Pharms reported a revenue of $216.11M.
What is the EBITDA for Vanda Pharms?
Vanda Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$139.25M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Vanda Pharms?
Vanda Pharms has a free cash flow of -$110.44M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Vanda Pharms have, and what sector and industry does it belong to?
Vanda Pharms employs approximately 533 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Vanda Pharms's shares?
The free float of Vanda Pharms is 54.07M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $467.54M
- EPS (TTM)
- -$3.736
- Free Float
- 54.07M
- Revenue (TTM)
- $216.11M
- EBITDA (TTM)
- -$139.25M
- Free Cashflow (TTM)
- -$110.44M
Pricing
- 1D span
- $8.692$9.49
- 52W span
- $3.81$9.93
Analyst Ratings
The price target is $15.50 and the stock is covered by 5 analysts.
Buy
4
Hold
1
Sell
0
Information
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.
- Employees
- 533
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- VNDA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet